Background. Regulation of myometrial progesterone receptor (PR) expression is an unresolved issue central to understanding the mechanism of functional progesterone withdrawal and initiation of labor in women. Objectives. To determine whether pregnant human myometrium undergoes culture-induced changes in PR isoform expression ex situ and, further, to determine if conditions approaching the in vivo environment stabilise PR isoform expression in culture.

Methods. Term nonlaboring human myometrial tissues were cultured under specific conditions: serum supplementation, steroids, stretch, cAMP, PMA, PGF \textsubscript{2}\textalpha, NF-\kappaB inhibitors, or TSA. Following 48 h culture, PR-T, PR-A, and PR-B mRNA levels were determined using qRT-PCR. PR-A/PR-B ratios were calculated. Results. PR-T and PR-A expression and the PR-A/PR-B ratio significantly increased in culture. Steroids prevented the culture-induced increase in PR-T and PR-A expression. Stretch blocked the effects of steroids on PR-T and PR-A expression. PMA further increased the PR-A/PR-B ratio, while TSA blocked culture-induced increases of PR-A expression and the PR-A/PR-B ratio. Conclusion. Human myometrial tissue in culture undergoes changes in PR gene expression consistent with transition toward a laboring phenotype. TSA maintained the nonlaboring PR isoform expression pattern. This suggests that preserving histone and/or nonhistone protein acetylation is critical for maintaining the progesterone dependent quiescent phenotype of human myometrium in culture.
decreases progesterone responsiveness [3, 5, 6, 19]. Recent
work has also shown that PR-A ligand-independently stim-
ulates the expression of the key labor promoting gene CaX3
[20]. Thus, genomic progesterone responsiveness is believed
to be regulated by the opposing actions of PR-A and PR-B and
is inversely associated with the PR-A/PR-B ratio [3, 5, 6, 19].
Indeed, several studies, including our own, have shown that
myometrial expression of PR-A has significantly increased
late in human pregnancy and with the onset of labor [21–24].

Elucidating the mechanism of functional progesterone
withdrawal is therefore important for understanding the
mechanisms regulating the balance between uterine quies-
cence and contractions. Outside of clinical trials, researchers
are primarily limited to observational studies on human
pregnancy. Interventional studies rely on animal models of
pregnancy as well as on in vitro experiments using human
myometrial smooth muscle cells and tissues. Human cell
cultures are a valuable in vitro tool used to gain insight into
numerous physiological and pathological processes; however,
concerns have been raised about the lifespan of cultured
primary cells [25] as well as their ability to remain to be
representative of the tissue of origin [26–29]. The use of ex
vivo myometrial tissue may represent the in vivo phenotype
more closely and can involve utilizing smooth muscle biopsy
samples as small pieces or dissecting the tissue into strips.
Tissue strips are primarily utilized to examine myometrial
contractility [30–33] such as the dynamic phosphorylation
events that occur in phase with contractions [34, 35].

Although the use of ex vivo tissues pieces and strips has
greatly facilitated studies into gene expression and regulation,
both approaches rely on the assumption that the tissue
phenotype remains stable across the course of the study. For
instance, it is assumed that nonlaboring myometrium retains
a nonlaboring phenotype ex vivo providing an experimental
system to induce labor-associated changes. Myometrial strips
from nonlaboring pregnant women, however, spontaneously
develop contractions ex vivo over the course of just 1–2 h,
suggesting a rapid transition away from the nonlaboring in
vivo phenotype [30, 33, 35]. Furthermore, tissue incubation
studies are routinely performed for 48 h or more; therefore
the transition away from the original phenotype may be even
more pronounced after 48 h culture in vitro.

The aim of this study was to determine if nonlaboring
myometrial tissue pieces and strips undergo culture-induced
changes in PR expression that are consistent with transition
to a PR isoform expression pattern similar to labor. We
further aimed to identify culture conditions that could be
implemented to block or minimize such transition in vitro,
presenting researchers with a stable platform on which to
conduct experimental studies.

Here we report that nonlaboring human myometrium
undergoes culture-induced changes in PR isoform expression
in vitro comparable with the changes attributed to functional
progesterone withdrawal at labor. We further report that
supplementing media with the histone deacetylase inhibitor
(HDACi), trichostatin A (TSA), prevents the culture-induced
functional progesterone withdrawal phenomenon by main-
taining a low PR-A/PR-B ratio, consistent with maintenance
of a nonlaboring phenotype.

2. Materials and Methods

2.1. Consumables and Reagents. Superscript III First-Strand
Synthesis System, Ultrapure Glycogen, UltraPure Agarose,
and Trackit 100 BP DNA ladder were purchased from
Invitrogen (Carlsbad, USA). Trizol Reagent and Turbo
DNA-free 50 reactions were from Ambion (Thermo Fisher).
Alien QRT-PCR Inhibitor Alert 400 Reactions were pur-
chased from Integrated Sciences Pty (Sydney, Australia).
(R)-MGI32, BAY-11-7085, Phorbol Myristate Acetate (PMA),
and Prostaglandin F2α (PGF2α) were obtained from Cayman
Chemical Company (Michigan, USA). 8-Bromoadenosine
3′,5′-cyclic monophosphate (8-Br-cAMP), PCR primers,
progesterone, and estradiol were purchased from Sigma (St
Louis, USA). 2 mL 2.8 mm ceramic bead kits (CK28-R) for
the Precellys homogenizer (Bertin Instruments, France) were
purchased from Thermo Fischer Scientific (Melbourne,
Australia). L-Glutamine, Sodium Pyruvate, Gentamicin, HEPES,
Dulbecco's Modified Eagle Medium (DMEM), and Charcoal
Stripped Fetal Bovine Serum were obtained from Gibco
(Carlsbad, USA). SYBR Green 2x Master mix was from
Applied Biosystems (Carlsbad, USA), TSA was supplied by
Bio-Scientific Pty. Ltd. (Sydney, Australia).

2.2. Myometrial Tissue Acquisition. These studies were ap-
proved by the Hunter and New England Area Human Research
Ethics Committee and the University of Newcastle Human
Ethics Committee (02/06/12/3.13). Human myometrial sam-
ple were obtained from the lower uterine segment during
elective Caesarean section (CS) of singleton term pregnancies
(38.2–39.6 weeks' gestation). Patient body mass index (BMI)
range was 18.3–38.0, and none of the patients were in-labor.
The indications for elective CS were previous CS, placenta
praevia, fetal distress, or breach presentation. Women were
excluded if they were given steroids. Following delivery of the
placenta, 5 units of syntocinon were administrated directly
into an intravenous line as part of standard care for the pre-
vention of postpartum hemorrhage. Samples were therefore
exposed to oxytocin for a brief period of time (3 min). All
samples were placed on ice in serum-free medium containing
DMEM with high glucose, 2 mM L-Glutamine, 1 mM Sodium
Pyruvate, 40 μg/mL Gentamicin, and 10 mM HEPES for the
transfer to the laboratory.

2.3. Myometrial Tissue (Explant) Culture. Approximately
100 μg tissue from each sample was immediately snap-frozen
in liquid nitrogen for subsequent analysis. The remaining
myometrium was dissected into approximately 2 × 2 × 2 mm
pieces and washed in serum-free media. Samples were then
incubated in serum-free or 5% (v/v) charcoal stripped serum-
(CSS)-supplemented media in a 37°C, 95% air/5% CO2
humidified incubator for 48 h. The 5% CSS-supplemented
media contained DMEM with high glucose, 2 mM L-
Glutamine, 1 mM Sodium Pyruvate, 40 μg/mL Gentamicin,
and 10 mM HEPES. To determine the effects of steroids,
myometrial samples were incubated with physiological con-
centrations of progesterone (P4; 500 nM) and/or estradiol
(E2; 400 nM) [14] in a 37°C, 95% air/5% CO2 humidified
incubator for 48 hours. To determine the effect of stretch
on human myometrium, myometrial tissue strips (2 × 2 × 10 mm) were cultured in 5% CSS-containing media for 48 h in a 37°C, 95% air/5% CO₂ humidified incubator while being subjected to 0, 1, or 3 g of constant stretch. Constant stretch was applied by using nylon thread to attach stainless steel weights to the ends of strips and then suspending the strips in 30 mL of culture media in 50 mL tubes (strips subjected to 0 g only were tied at one end). To determine the effect of stretch and steroids on human myometrium, myometrial strips were cultured in 5% CSS-containing media with 500 nM P4 and 400 nM E2 for 48 h in a 37°C, 95% air/5% CO₂ humidified incubator while being subjected to 0, 1, or 3 g of stretch. To determine the effects of the signalling pathways involved in myometrial relaxation and contraction, myometrial tissues were incubated for 48 h a 37°C, 95% air/5% CO₂ in 5% CSS-containing media supplemented with the cAMP analogue 8-Br-cAMP (250 μM), PMA (0.1, 1.0 μM), Pgf₂α (1, 10, 100, and 1000 nM), or the nuclear factor-kB (NF-kB) inhibitors MG-132 (2.0, 5.0, and 10.0 μM) and BAY-II-7085 (2.0, 5.0, and 10.0 μM) individually or in combination (10.0 μM MG-132 + 10.0 μM BAY-II-7085). Furthermore, myometrial tissues were incubated for 48 h a 37°C, 95% air/5% CO₂ in 5% CSS-containing media supplemented with TSA (0.5, 1.0, 2.5, or 5.0 μM). Vehicle was DMSO (0.1%). Following each incubation, the media were decanted and tissue pieces or strips were snap-frozen using liquid nitrogen and stored at −80°C for subsequent analyses.

2.4. RNA Extraction, Reverse Transcription, and Real-Time Quantitative PCR. RNA was extracted from 100 mg of tissue using TRIzol Reagent (Thermo Fisher) according to the manufacturer’s protocol. Homogenization of tissue in TRIzol Reagent was performed using a Precellys 24 homogenizer (Bertin Instruments, France). Following extraction, RNA samples were purified using the TURBO DNA-free kit (Thermo Fisher). An ND-1000 spectrophotometer was used to measure RNA concentration (absorbance at 260 nm (A₂₆₀) and 280 nm (A₂₈₀)) and purity. RNA integrity was checked by agarose gel electrophoresis. Each RNA sample (0.5 μg of total RNA) was spiked with 0.5 × 10⁷ copies of Alien RNA and reverse-transcribed using the SuperScript III First-Strand Synthesis System with random hexamer primers. Quantitative RT-PCR was performed using an ABI 7500 Sequence Detector. No-reverse transcription (no-RT) negative controls were prepared for each sample to ensure there was no DNA contamination. The final volume of each PCR reaction was 20 μL containing 10 μL of 2x SYBR Green PCR Master Mix (Thermo Fisher), master mix cDNA template (corresponding to 10 ng of reverse transcribed RNA), target cDNA-specific forward and reverse primers, and MilliQ water. For the reference gene (Alien primer), the final volume was also 20 μL with 1.0 μL of 2.5 μM of Alien Primer Mix, 10 μL of 2x SYBR Green PCR, and the same amount of cDNA as the target genes and MilliQ water. No-template control samples (NTCs) were included in each PCR plate to detect any contamination and primer-dimers. PCR primers were designed using Primer Express and are shown in the Table 1.

| Primer  | Primer sequence (5’-3’)   | Amplicon size | GeneBank #   |
|---------|---------------------------|---------------|--------------|
| PR-T    | F: GTGGGAGCTTGTAAGGTCCTCTTAA R: AAGGATGCAGTCATTTCTTCCA | 83            | NM000926.4   |
| PR-B    | F: TCGGACACCTTGCGTGAAATG R: CAGG GCCAGGGAGAGTAG | 68            | NM000926.4   |

PR-T, progesterone receptor total; PR-B, progesterone receptor isoform B.

2.5. Data and Statistical Analysis. All mRNA abundance data were expressed relative to the Alien reference RNA. The relative mRNA abundance was calculated using the delta C (ΔCt) method [36]. The relative mRNA abundance of PR-A was calculated by subtracting the relative mRNA abundance of PR-B from that of PR-T. All mRNA relative abundance values were checked for normal distribution using Shapiro-Wilk normality test and if data was not normally distributed, then it was logarithmically transformed to approach normal distribution. Statistical analyses were conducted with Graph-Pad Prism software (San Diego, CA, USA). Graphical data are presented as mean ± SEM. For comparison between two groups, Student’s t-test was used. For multiple comparisons, a one-way analysis of variance (ANOVA) followed by post hoc test of Dunnett multiple comparisons was used. p values ≤ 0.05 were considered statistically significant.

3. Results

3.1. Culture-Induced Changes in Myometrial PR Isoform Expression over Time. Myometrial tissues were incubated for 0, 1, 2, 6, 24, or 48 h in serum-free media to determine changes in PR isoform expression that occurred upon being removed from the in vivo environment and cultured in vitro. PR-T, PR-B, and PR-A mRNA abundance were determined across the timeline and the PR-A/PR-B ratio calculated.

PR-T mRNA abundance was significantly increased after 48 h culture (p = 0.0301) (Figure I(a)) and was attributable to increased PR-A mRNA abundance, which was significantly increased beyond 24 h culture (p = 0.0121) (Figure I(b)). PR-B mRNA abundance remained relatively constant (Figure I(c)). The PR-A/PR-B ratio was significantly increased after 6 h in vitro culture (p = 0.0487) and highly significant beyond 24 h culture (p < 0.0001) (Figure I(d)).

3.2. Controlling Changes in PR Isoform Expression Using Serum. CSS is often used in myometrial culture media [37–39]. Having observed a culture-induced increase in PR-A expression (and thus PR-T expression), we examined whether supplementing media with 5% CSS affected culture-induced
changes in PR expression. CSS supplementation had no effect on culture-induced changes in PR expression. After 48 h culture, there was no significant difference in PR-T, PR-A, or PR-B mRNA abundance. Furthermore, there was no significant difference in PR-A/PR-B expression ratio between myometrial tissues cultured in serum-free media versus 5% CSS-supplemented media (Figure 2).

3.3. Controlling Changes in PR Isoform Expression Using Steroids. Relative abundance of PR-T, PR-A, and PR-B mRNA was measured in myometrial tissues incubated for 48 h in the presence of 500 nM P4 or 500 nM P4 + 400 nM E2, which are hormone concentrations in term maternal plasma [14].

PR-T mRNA abundance significantly increased in DMSO-treated (control) tissues following 48 h incubation (\( p = 0.0317 \)) (Figure 3(a)). Upon supplementing media with 500 nM P4, PR-T mRNA abundance was reduced after 48 h culture relative to the control; however, the effect did not reach statistical significance (\( p = 0.2457 \)) (Figure 3(a)). Supplementing media with the combination of 500 nM P4 + 400 nM E2 prevented the increase in PR-T mRNA abundance to the extent that there was a significant difference relative to 48 h DMSO-treated control tissues (\( p = 0.0232 \)) (Figure 3(a)).

Similarly, PR-A mRNA abundance significantly increased in DMSO-treated (control) tissues following 48 h incubation (\( p = 0.0036 \)) and supplementing media with 500 nM P4 reduced PR-A mRNA abundance after 48 h relative to the control; however, the difference was not statistically significant (\( p = 0.3234 \)) relative to 48 h DMSO-treated control tissues (Figure 3(b)). Supplementing media with the combination of 500 nM P4 + 400 nM E2 prevented the increase in PR-A mRNA abundance to the extent that there was a significant
Figure 2: Effect of serum on culture-induced changes in PR isoform expression in vitro: relative mRNA abundance of PR-T, PR-A, and PR-B was measured in term nonlaboring myometrial tissue samples following 48 h incubation in serum-free media or media supplemented with 5% CSS (n = 9) and expressed relative to Alien reference. In addition, PR-A/PR-B expression ratio was calculated. (a) PR-T mRNA abundance. (b) PR-A mRNA abundance. (c) PR-B mRNA abundance. (d) PR-A/PR-B expression ratio. Data was checked for normality (Shapiro-Wilk normality test) and if necessary was logarithmically transformed to approach normal distribution (Shapiro-Wilk normality test). Data was analysed using 1-way ANOVA with multiple comparisons (Dunnett). Data are mean ± SEM.

PR-B mRNA abundance remained unchanged over 48 h of culture and supplementing media with 500 nM P4 alone, or 500 nM P4 + 400 nM E2, had no significant effect on PR-B mRNA abundance (Figure 3(c)).

The PR-A/PR-B expression ratio significantly increased in DMSO-treated (control) tissues following 48 h incubation (p = 0.0054) (Figure 3(d)). P4-supplementation had no effect on the PR-A/PR-B expression ratio relative to DMSO-treated control tissues and remained significantly elevated compared to fresh tissues (p = 0.0006) (Figure 3(d)). Similarly, the combination of 500 nM P4 + 400 nM E2 had no significant effect on the PR-A/PR-B expression ratio after 48 h relative to DMSO-treated control tissues (p > 0.9999), and the PR-A/PR-B expression ratio remained significantly elevated relative to the fresh tissues (p = 0.0053) (Figure 3(d)).

3.4. Controlling Changes in PR Isoform Expression Using Stretch. Myometrial tissue strips were subjected to 0, 1, or 3 g of stretch for 48 h to determine whether applying stretch to the muscle influenced culture-induced changes in PR isoform expression. The effect of stretch was investigated in the absence and presence of steroids (500 nM P4 + 400 nM E2).

Stretch (1 or 3 g) applied to myometrial strips for 48 h had no effect on PR-T expression (Figure 4(a)) relative to nonstretched (0 g) control strips. Interestingly, stretch in the presence of 500 nM P4 + 400 nM E2 for 48 h also had no significant effect on PR-T mRNA levels (Figure 4(b)),
indicating that P4 + E2 was no longer effective in decreasing PR-T mRNA abundance compared to fresh tissues.

Similarly, stretch applied to myometrial strips for 48 h had no effect on PR-A mRNA expression (Figure 4(c)). Stretch applied in the presence of 500 nM P4 + 400 nM E2 likewise had no effect (Figure 4(d)), indicating that P4 + E2 was no longer effective in preventing culture-induced increase in PR-A mRNA abundance compared to fresh tissues.

As seen in Figure 4(e), 0–3 g stretch had no effect on PR-B expression in the tissue strips. Stretch in the presence of 500 nM P4 + 400 nM E2 for 48 h also had no significant effect on PR-B mRNA levels (Figure 4(f)).

The PR-A/PR-B expression ratio was calculated and there was significant increase following 48 h incubation in nonstretched (0 g) control strips when compared to fresh tissues (p = 0.0164) (Figure 4(g)). Applying stretch (1 or 3 g) to myometrial strips for 48 h had no effect on expression ratio when compared to nonstretched strips (Figure 4(g)). Further, there was significant increase in PR-A/PR-B expression ratio following 48 h incubation in nonstretched (0 g) control strips in the presence of 500 nM P4 + 400 nM E2 when compared to fresh tissues (p = 0.0067) (Figure 4(h)). Stretch (1 or 3 g) applied in the presence of 500 nM P4 + 400 nM E2 had no effect on expression ratio after 48 h culture when compared to control strips (Figure 4(h)).

3.5. Controlling Changes in PR Isoform Expression Using Cyclic-AMP and PMA. Relative abundance of PR-T, PR-A, and PR-B mRNA was measured in myometrial tissue incubated for 48 h in the presence of 8-Br-cAMP (250 μM), PMA (0.1 and 1.0 μM), or vehicle (DMSO).

Supplementing culture media with 250 μM 8-Br-cAMP had no effect on mRNA abundance for PR-T, PR-A, or PR-B (Figures 5(a)–5(c)). The PR-A/PR-B expression ratio in DMSO-treated tissues was significantly elevated following 48 h incubation when compared to fresh tissues (p = 0.0236)
Figure 4: Effect of stretch in the absence or presence of steroids on culture-induced changes in PR isoform expression in vitro: Relative mRNA abundance of PR-T, PR-A, and PR-B was measured in term nonlaboring myometrial strips while applying 0, 1, and 3 g of stretch for 48 h \((n=5)\), as well as in presence of steroids \((500 \text{nM P}4 + 400 \text{nM E}2)\) while applying 0, 1, and 3 g of stretch for 48 h \((n=3)\), and expressed relative to Alien reference. In addition, PR-A/PR-B expression ratio was calculated. (a) Effect of stretch on PR-T mRNA abundance. (b) Effect of stretch and steroids on PR-T mRNA abundance. (c) Effect of stretch on PR-A mRNA abundance. (d) Effect of stretch and steroids on PR-A mRNA abundance. (e) Effect of stretch on PR-B mRNA abundance. (f) Effect of stretch and steroids on PR-B mRNA abundance. (g) Effect of stretch on PR-A/PR-B expression ratio. (h) Effect of stretch and steroids on PR-A/PR-B expression ratio. Data was checked for normality (Shapiro-Wilk normality test) and if necessary was logarithmically transformed to approach normal distribution (Shapiro-Wilk normality test). Data was analysed using 1-way ANOVA with multiple comparisons (Dunnett). Data are mean ± SEM.
Figure 5: Effect of cAMP and PMA on culture-induced changes in PR isoform expression in vitro: Relative mRNA abundance of PR-T, PR-A, and PR-B was measured in term nonlaboring myometrial tissue samples (n = 3) following 48 h incubation in the presence of 8-Br-cAMP (250 μM) or PMA (0.1 and 1.0 μM) and expressed relative to Alien reference. In addition, PR-A/PR-B expression ratio was calculated. (a) Effect of 8-Br-cAMP on PR-T mRNA abundance. (b) Effect of 8-Br-cAMP on PR-A mRNA abundance. (c) Effect of 8-Br-cAMP on PR-B mRNA abundance. (d) Effect of 8-Br-cAMP on PR-A/PR-B expression ratio. (e) Effect of PMA on PR-T mRNA abundance. (f) Effect of PMA on PR-A mRNA abundance. (g) Effect of PMA on PR-B mRNA abundance. (h) Effect of PMA on PR-A/PR-B expression ratio. Data was checked for normality (Shapiro-Wilk normality test) and then analysed using 1-way ANOVA with multiple comparisons (Dunnett). Data are mean ± SEM.

was measured in myometrial tissue incubated for 48 h in the presence of PGF$_{2\alpha}$ (1, 10, 100, or 1000 nM) or vehicle (DMSO). Following 48 h incubation PR-T mRNA abundance in DMSO-treated control tissues was elevated relative to fresh tissues but did not reach statistical significance (Figure 6(a)). PGF$_{2\alpha}$ treatments had no effect on PR-T mRNA abundance relative to 48 h DMSO-treated control tissues (Figure 6(a)).

PR-A mRNA abundance was significantly increased in DMSO-treated control tissues relative to fresh tissues (p = 0.0451) (Figure 6(b)). PGF$_{2\alpha}$ treatments had no effect on PR-A mRNA abundance relative to 48 h DMSO-treated control tissues (Figure 6(b)). PR-B mRNA abundance remained unchanged following 48 h incubation and was not affected by PGF$_{2\alpha}$ treatments (Figure 6(c)).

In 48 h DMSO-treated tissue the PR-A/PR-B expression ratio was significantly elevated relative to fresh tissues (p = 0.0294) (Figure 6(d)). PGF$_{2\alpha}$ supplementation (1, 10, 100, or
3.7. Controlling Changes in PR Isoform Expression Using NF-κB Inhibitors. The NF-κB inhibitors, MG-132 and BAY-11-7085, were employed to test whether NF-κB pathway activation was involved in the PR isoform expression changes induced by in vitro culture.

Following 48 h incubation, there was no significant difference in PR-T mRNA abundance between vehicle-treated tissues and fresh tissues (Figure 7(a)). Incubating myometrial samples with 2.0, 5.0, or 10.0 µM MG-132 or BAY-11-7085 individually or in combination (10 µM each) had no effect on PR-T mRNA abundance relative to vehicle-treated tissues (Figure 7(a)).

PR-A mRNA abundance in vehicle-treated tissues significantly increased compared to fresh tissues following 48 h incubation (p = 0.0170) (Figure 7(b)). Supplementing culture media with 2.0, 5.0, or 10.0 µM MG-132 or BAY-11-7085 individually or in combination (10 µM each) had no significant effect on PR-A mRNA abundance relative to 48 h vehicle-treated tissues (Figure 7(b)).

Following 48 h incubation, there was no significant difference in PR-B mRNA abundance between vehicle-treated tissues and fresh tissues (Figure 7(c)). Incubating myometrial samples with 2.0, 5.0, or 10.0 µM MG-132 or BAY-11-7085 individually or in combination (10 µM each) had no effect on PR-B mRNA abundance relative to vehicle-treated tissues (Figure 7(c)).

Following 48 h incubation, the PR-A/PR-B expression ratio was significantly elevated in vehicle-treated tissues relative to DMSO-treated control tissues (Figure 6(d)).
compared to fresh tissues ($p = 0.0011$) (Figure 7(d)). Supplementing culture media with 2.0, 5.0, or 10.0 μM MG-132 or BAY-11-7085 individually or in combination (10 μM each) had no effect on PR-A/PR-B expression ratio compared to the vehicle-treated tissues (Figure 7(d)).

### 3.8. Controlling Changes in PR Isoform Expression Using TSA

Relative abundance of PR-T, PR-A, and PR-B mRNA was measured in myometrial tissue incubated for 48 h in the presence of TSA (0.5, 1.0, 2.5, and 5.0 μM) or vehicle (DMSO).

There was no significant difference in PR-T mRNA abundance between 48 h vehicle-treated tissues and fresh tissues (Figure 8(a)). Incubating myometrical samples with 0.5, 1.0, 2.5, and 5.0 μM TSA had no effect PR-T mRNA abundance relative to 48 h vehicle-treated tissues (Figure 8(a)).

PR-A mRNA abundance was significantly increased in 48 h vehicle-treated tissues relative to fresh tissues ($p = 0.0431$) (Figure 8(b)). Culture-induced increases in PR-A mRNA abundance were inhibited by supplementing media with TSA. The extent of inhibition reached statistical significance, relative to 48 h vehicle-treated tissue, at 5.0 μM TSA ($p = 0.0305$) (Figure 8(b)).

PR-B mRNA abundance did not change following 48 h incubation and was unaffected by TSA treatments relative to vehicle-treated tissues (Figure 8(c)).

Following 48 h incubation, the PR-A/PR-B expression ratio was significantly elevated in vehicle-treated tissues compared to fresh tissues ($p = 0.0002$) (Figure 8(d)). The PR-A/PR-B expression ratio was significantly lower in tissue treated with 2.5 and 5.0 μM TSA ($p = 0.0003$ and $p < 0.0001$, resp.) relative to 48 h vehicle-treated tissues (Figure 8(d)). TSA dose-dependently prevented culture-induced increases in the PR-A/PR-B expression ratio.
4. Discussion

Human tissue and cell cultures are a valuable in vitro tool used to investigate the maintenance of uterine quiescence and the mechanisms by which the myometrium transforms to an actively contracting organ at labor. Our previous results show that, upon culturing nonlaboring myometrial tissues in vitro, the tissue undergoes culture-induced changes in expression of the key myometrial genes *ESR1*, *PTGS2*, and *OXTR*, which are consistent with transition toward a procontractile, laboring phenotype (under review). In light of this evidence, we further examined whether *PR* isoform expression undergoes culture-induced changes that are consistent with transition to a procontractile, laboring phenotype.

In this study we examined changes in *PR* isoform expression via determining mRNA levels, an approach which is consistent with other studies in the field [40]. Nevertheless, we are aware that *PR* isoform protein levels may reflect *PR* function more closely than mRNA abundance especially in pregnancies complicated by intrauterine inflammation [41]. Previous studies have demonstrated, however, that there is close correspondence between *PR* isoform mRNA and protein expression changes in the human myometrium at normal term labor [23, 24], which is the context of this study. Furthermore, recent studies examining protein profiles in mammalian cells have found that transcription, not translation, mostly determines protein abundance [42] and that during periods of dynamic change, such as phenotype transition, changes in mRNA abundance play a dominant role in determining changes in protein levels [43]. Overall, assessing myometrial PR function by determining *PR-A* and *PR-B* mRNA levels appears a reliable approach in the patient population we examined.

Tissue incubation studies are routinely performed for 48 h or more [38, 39, 44]. Considering that nonlaboring human myometrium develops contractility in vitro in just 1-2 h [30, 33, 35, 45], the transition away from the original phenotype may be even more pronounced after such 48 h
incubations. Our results illustrate that, in human myometrial pieces, PR-A mRNA abundance begins increasing after just 1 h culture. With PR-B mRNA abundance remaining constant, a statistically significant increase in the PR-A/PR-B expression ratio was evident after just 6 h culture (Figure 1). Previous studies using enzyme-immunoassays found that samples collected from the upper segment myometrium during labor had higher total PR concentrations than samples collected prior to labor [46]. Haluska et al. [22] used rhesus monkey, another genus that lacks a systemic progesterone withdrawal, to look at the changes in PR isoform concentrations. They found that there was no change in total PR expression during the transition from late pregnancy to labor; however, they did find a significant shift in the ratio of PR isoforms [22]. More specifically, the myometrial PR-A/PR-B ratio increased significantly from late pregnancy to spontaneous labor at term [22]. Furthermore, Pieber et al. [47] performed immunoblot analyses on lower segment myometrium from pregnant women and reported an increase in the PR-A protein abundance during labor, while levels of PR-B were not altered by labor status. Recently, our group showed that the onset of labor is associated with increased abundance of PR-A mRNA and an increase in the PR-A/PR-B expression ratio in term human myometrium [24]. Our group has also found that the PR-A/PR-B protein ratio in pregnant human myometrium was 0.5 (a PR-B dominant state) at 30 weeks’ gestation, which then increased to 1.0 at term prior to the onset of labor, and at the time of the labor the ratio increased further to 3.0 (a PR-A dominant state) [23]. These results indicate that PR mRNA levels reflect PR protein levels in human myometrium. Our observation that PR-T and PR-A mRNA abundance as well as the PR-A/PR-B expression ratio increased during culture is therefore consistent with the tissue transitioning to a labor-like state as a consequence of in vitro conditions.

This finding has implications for the interpretation in vitro of studies performed on nonlaboring myometrium, which may have in fact already transitioned to a labor-like phenotype during the early stages of the study and may therefore have affected the outcome of the study. To address this, we sought to identify culture conditions that could be implemented to maintain a nonlaboring state whereby human myometrium retained a low PR-A/PR-B expression ratio (a PR-B dominant state), thereby providing a more appropriate in vitro model for conducting studies into myometrial biology.

Previous studies utilizing myometrial culture (explants) often included CSS in their media [37–39]. Therefore, we examined whether supplementing culture media with 5% CSS affected culture-induced changes in PR isoform expression. Surprisingly, 5% CSS had no significant effect on PR-T, PR-A, or PR-B mRNA abundance after 48 h culture and consequently had no effect on the PR-A/PR-B expression ratio (Figure 2). While supplementing media with serum is common practice during in vitro culture, our results indicate that this practice is not sufficient to prevent culture-induced changes in PR isoform expression.

The steroid hormone progesterone plays a crucial role in maintaining pregnancy by promoting myometrial quiescence and relaxation [5–7]. In contrast to most mammalian species [8–12], no decrease in maternal serum levels of progesterone can be observed in humans and higher primates prior to the onset of labor [13–15]. Thus, the term “functional progesterone withdrawal” has been used to describe the withdrawal of progesterone action. Once myometrial tissue is removed from in vivo environment and cultured in vitro, the high plasma levels of progesterone are no longer present, which could possibly account for culture-induced changes in PR expression in vitro. To explore this, we incubated myometrial tissues in media that contained physiological concentrations of progesterone. Supplementing media with progesterone alone was not sufficient to prevent the culture-induced increases in PR-T and PR-A mRNA abundance. Moreover, progesterone decreased PR-B mRNA abundance; however, it was not statistically significant; nevertheless this further exacerbated the increase in the PR-A/PR-B expression ratio (Figure 3). A previous study using myometrial strips showed that progesterone exerts rapid inhibition of the amplitude of myometrial contractions in vitro [30]. More recently, Baumbach et al. [31] investigated the suppression of uterine contractility using progesterone alone and in a combination with various tocolytics and found that progesterone alone had little effect inhibiting contractility [31]. This is consistent with our results where progesterone alone did not prevent culture-induced increases in PR-T and PR-A mRNA abundance.

In numerous mammalian species, the process of parturition, especially transformation of the myometrium from the quiescent to a contractile state, necessitates an increase in circulating estrogen concentrations prior to the onset of labor [11, 14, 48, 49]. In humans and higher primates, however, maternal estrogen levels are high for most of pregnancy and remain elevated during parturition and delivery [14, 50, 51]. Furthermore, our group reported a correlation between estrogen receptor 1 (ESR1) mRNA levels and the PR-A/PR-B mRNA ratio, which is indicative of a functional link between the PR and ESR1 systems [24]. In addition, this link between the two systems is in agreement with studies performed in a range of species demonstrating that progesterone decreases expression of ESR1, thus decreasing uterine responsiveness to estrogen [52, 53]. These results imply that the interaction between progesterone and PR-B suppresses ESR1 expression, therefore rendering the myometrium refractory to circulating estrogen [19]. However, with advancing gestation there is an increase in the expression of PR-A, which in turn represses the transcriptional activity of PR-B, and as a result the PR-B-mediated inhibition of ESR1 expression is withdrawn [19]. Once myometrial tissue is removed from in vivo environment and cultured in vitro, the high plasma levels of progesterone and estrogen are no longer present, thereby removing the functional link between progesterone and estrogen [24] which could possibly account for the observed culture-induced changes in PR expression in vitro. To explore this, we incubated myometrial tissue in media that contained physiological concentrations of P4 and E2. The combination of P4 and E2 prevented culture-induced increase in PR-T and PR-A mRNA abundance observed in vitro. However, P4 in combination with E2 also decreased PR-B mRNA abundance; nevertheless this decrease was not statistically significant.
As such, after 48 h culture the PR-A/PR-B expression ratio had still increased relative to fresh tissue and adopted a PR-A dominant state (Figure 3).

Throughout normal pregnancy the uterus increases several-fold in size by both hyperplasia and hypertrophy to accommodate the growing fetus and placenta [54, 55]. A previous study using term nonlaboring human myometrium tissue showed that stretch applied to myometrial cells in culture resulted in decreased PR-T and PR-B mRNA expression [56]. We found that constant stretch, applied by means of hanging 1 or 3 g weights from tissue strips, had no effect on culture-induced changes in PR isoform expression (Figure 4). This is inconsistent with a previous report where stretch downregulated PR-T and PR-B expression; however, it should be noted that those studies used myometrial cells while our study uses myometrial tissue strips [56]. Previous animal studies suggest that progesterone is responsible for maintaining uterine quiescence and promoting myometrial hyperplasia and hypertrophy to inhibit any increase in uterine wall tension [57–60]. In addition, human studies show that, in a progesterone-dominated endocrine environment, moderate stretch possibly maintains relaxation and quiescence; however, in the absence of progesterone or excessive stretch, the uterus starts to contract [54, 55]. Interestingly, although stretch did not directly affect the culture-induced changes in PR-T, PR-A, or PR-B expression, the application of stretch prevented steroids (P4 + E2) from blocking culture-induced increases in PR-T and PR-A mRNA expression and prevented steroids (P4 + E2) from decreasing PR-B mRNA expression (Figures 3 and 4).

There is now extensive evidence to suggest that components of the cAMP signalling pathway are upregulated in the human myometrium throughout pregnancy to maintain uterine quiescence until term [61–65]. Moreover, our group showed that, in PHM1-31 cells, a pregnant human myometrial cell line, 8-Br-cAMP, an agonist for the protein kinase A (PKA) pathway, increased the expression of both PR-A and PR-B but had a net effect of decreasing the PR-A/PR-B expression ratio [66]. Supplementing media with a cAMP analogue was therefore examined as a potential means to prevent culture-induced changes in PR isoform expression. Although cAMP has a well-defined role in promoting myometrial relaxation, supplementing media with 8-Br-cAMP failed to prevent culture-induced changes in PR-T or PR-A mRNA abundance and increased PR-A/PR-B expression ratio (Figure 5).

In contrast to previously discussed treatments that attempted to prevent culture-induced changes in PR isoform expression, we also examined the effect of the procontractile agent, PMA, to determine whether PR expression would be driven further toward a labor-like state. Previous studies by our group show that PKC activation by PMA increased the PR-A/PR-B expression ratio by selectively increasing expression of PR-A [66]. This study found that supplementing culture with PMA further increased the PR-A/PR-B expression ratio in vitro, which was consistent with this procontractile agent driving further transition toward a laboring phenotype. Interestingly, PMA did not increase expression of PR-A but rather decreased expression of PR-B over the course of the myometrial culture (Figure 5).

There is increasing evidence that locally produced immune/inflammatory cytokines, particularly proinflammatory mediators, are involved in normal term labor as well as infection-associated preterm labor [67–69]. In human pregnancy, administration of PGs or PG analogues at any stage of pregnancy transforms the myometrium and cervix and induces labor [69–73]. Previously, our group has tested the hypothesis that PGs, specifically PGF2α, induce functional progesterone withdrawal by altering myometrial PR expression in PHM1-31 cells [66]. PGF2α produced a dose-dependent increase in expression of PR-A, but not PR-B, thereby resulting in an increase in the PR-A/PR-B expression ratio [66]. In this study, supplementing media with PGF2α had no effect on PR mRNA abundance and therefore did not prevent culture-induced changes in the PR-A/PR-B expression ratio (Figure 6). This is not consistent with previous results where PGF2α increased the PR-A/PR-B expression ratio by increasing PR-A expression [66].

Romero et al. [74] have shown that tissue-level inflammation in the myometrium, decidua, and fetal membranes plays a crucial role in the human parturition. In recent years, studies have demonstrated that myometrium in pregnant women at term exhibits biochemical and histological characteristics of inflammation, including increased expression of PGs, increased NF-κB activity, increased infiltration of neutrophils, and macrophages, which may precede the onset of active labor and is independent of infection [6, 8, 75–80]. Furthermore, studies using human myometrial cells have shown that progesterone inhibits the proinflammatory NF-κB transcription factor complex as a result of PR-induced expression of inhibitor-κB (IKBα), a major NF-κB repressor [81]. Supplementing media with NF-κB inhibitors therefore represented a potential means of preventing spontaneous changes in PR isoform expression. Supplementing media with MG-132 or BAY-11-7085 had no effect on PR-T, PR-A, and PR-B mRNA abundance and therefore did not prevent culture-induced changes in the PR-A/PR-B expression ratio (Figure 7).

Condon et al. [82] administered TSA, a specific and potent HDACi, to pregnant mice late in gestation and found increased histone H3 acetylation as well as a delay in the initiation of parturition by 24–48 h. Decreased histone acetylation in the pregnant uterus near term, caused by a marked decrease in expression of uterine coactivators with intrinsic histone acetyltransferase activity, might serve an important role in the loss of PR function, thus instigating a functional progesterone withdrawal and the initiation of labor [82]. Furthermore, Wilson et al. [83] used the mouse mammary tumor virus promoter to examine the impact of TSA on PR activated transcription and found that TSA removed the transcription factor nuclear factor I from the promoter and decreased PR-induced transcription [83]. Based on these results we hypothesised that TSA may modulate PR isoform expression and supplemented culture media with TSA in anticipation of maintaining a low PR-A/PR-B expression ratio in vitro. Excitingly, TSA produced a dose-dependent inhibition of culture-induced upregulation of PR-A mRNA.
abundance. With no effect of PR-B mRNA abundance, TSA was successful in maintaining a low PR-A/PR-B expression ratio over 48 h culture, consistent with freshly isolated term nonlaboring myometrium and consistent with preventing in vitro transformation to a laboring phenotype (Figure 8). Using TSA to maintain a low PR-A/PR-B ratio could have important clinical ramifications in that progesterone therapy is currently a leading strategy for the prevention of preterm birth (reviewed by van Zijl et al. [84]). Efficacy of progesterone administration may be enhanced if an agent such as TSA could be administered to preserve or even restore progesterone sensitivity in women with threatened preterm labor.

5. Conclusion

Concerns have previously been raised about the ability of primary cells in culture to remain representative of their tissues of origin. Adding to this concern, our previous study shows that term nonlaboring human myometrial tissue undergoes culture-induced changes in expression of ESR1, PTGS2, and OXTR that are consistent with transitioning toward a laboring phenotype. In this study we examined PR isoform expression and found that PR-T and PR-A mRNA expression increased in untreated tissue over 48 h culture. Additionally, the PR-A/PR-B expression ratio significantly increased, consistent with transition to a laboring phenotype. Through examining various culture conditions, we were able to maintain a nonlaboring state of PR isoform expression by supplementing culture media with TSA, which prevented the culture-induced increase in PR-A mRNA abundance and maintained a low PR-A/PR-B expression ratio. In summary, this study demonstrates that

(i) human myometrial tissues undergo culture-induced upregulation of PR-T and PR-A mRNA expression, which significantly increases the PR-A/PR-B expression ratio in vitro, even in nontreated tissue;
(ii) the combination of progesterone and estrogen downregulated PR-T and PR-A mRNA expression;
(iii) stretch had no direct effect on PR-T, PR-A, or PR-B expression, but it blocked the effects of progesterone and estrogen on PR-T and PR-A expression;
(iv) cAMP was unable to control culture-induced changes in PR expression;
(v) PMA further upregulated PR-A/PR-B expression ratio;
(vi) PGF2α had no effect of PR expression in vitro;
(vii) NF-κB inhibitors were unable to control culture-induced changes in PR expression;
(viii) TSA downregulated PR-A mRNA expression and downregulated PR-A/PR-B expression ratio.

Disclosure

The funding providers had no involvement in the study or production of this article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Marina Ilicic, Tamas Zakar, and Jonathan W. Paul conceived and designed the experiments. Marina Ilicic contributed to sample collection. Marina Ilicic and Jonathan W. Paul performed the experiments and contributed to data analysis and manuscript writing. Tamas Zakar and Jonathan W. Paul provided reagents and materials. Tamas Zakar contributed to manuscript editing.

Acknowledgments

This work was supported by grants from the National Health and Medical Research Council, Australia (NHMRC), the John Hunter Hospital Charitable Trust (JHHCT), and School of Medicine and Public Health Research Training Scheme (RTS). Facilities and infrastructure were provided by the University of Newcastle and Hunter Medical Research Institute (HMRI). The authors wish to thank the obstetricians from the John Hunter Hospital, NSW, their research midwife, Anne Wright, and the research participants who donated samples toward this study.

References

[1] J. R. G. Challis, D. M. Sloboda, N. Alfaidy et al., "Prostaglandins and mechanisms of preterm birth," Reproduction, vol. 124, no. 1, pp. 1–17, 2002.
[2] J. M. Dodd and C. A. Crowther, "The role of progesterone in prevention of preterm birth," International Journal of Women's Health, vol. 1, no. 1, pp. 73–84, 2010.
[3] S. Mesiano, "Myometrial progesterone responsiveness," Seminars in Reproductive Medicine, vol. 25, no. 1, pp. 5–13, 2007.
[4] S. C. Tough, "Preterm Birth and Healthy Outcomes Team: the science and strategy of team-based investigation," BMC Pregnancy and Childbirth, vol. 13, article SI, 2013.
[5] P. Arck, P. J. Hansen, B. M. Jericevic, M.-P. Piccinini, and J. Szekeres-Bartho, "Progesterone during pregnancy: endocrine-immune crosstalk in Mammalian Species and the role of stress," American Journal of Reproductive Immunology, vol. 58, no. 3, pp. 268–279, 2007.
[6] S. Astle, D. M. Slater, and S. Thornton, "The involvement of progesterone in the onset of human labour," European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 108, no. 2, pp. 177–181, 2003.
[7] A. Csapo, "Progesterone block," American Journal of Anatomy, vol. 98, no. 2, pp. 273–291, 1956.
[8] V. C. Allport, D. Pieber, D. M. Slater, R. Newton, J. O. White, and P. R. Bennett, "Human labour is associated with nuclear factor-NF-κB activity which mediates cyclo-oxygenase-2 expression and is involved in the functional progesterone withdrawal," Molecular Human Reproduction, vol. 7, no. 6, pp. 581–586, 2001.
[9] G. Liggins, "Initiation of Labour," Neonatology, vol. 55, no. 6, pp. 366–375, 1989.
[10] G. C. Liggins, R. J. Fairclough, S. A. Grieves, J. Z. Kendall, and B. S. Knox, "The mechanism of initiation of parturition in the ewe," Recent Prog Horm Res, vol. 29, pp. 111–159, 1973.
S. Mesiano, "Myometrial progesterone responsiveness and the control of human parturition," *Journal of the Society for Gynecologic Investigation*, vol. 11, no. 4, pp. 193–202, 2004.

I. R. Young, "The comparative physiology of parturition in mammals," *Front Horm Res*, vol. 27, pp. 10–30, 2001.

R. S. Boroditsky, F. I. Reyes, J. S. Winter, and C. Faiman, "Maternal serum estrogen and progesterone concentrations preceding normal labor," *Obstet Gynecol*, vol. 51, no. 6, pp. 686–91, 1978.

D. Tulchinsky, C. J. Hobel, E. Yeager, and J. R. Marshall, "Plasma estrone, estradiol, estriol, progesterone, and 17-hydroxyprogesterone in human pregnancy. I. Normal pregnancy," *American Journal of Obstetrics and Gynecology*, vol. 112, no. 8, pp. 1095–1100, 1972.

S. W. Walsh, F. Z. Stanczyk, and M. J. Novy, "Dihydropyrimidine treatment in the maternal, fetal, and amniotic fluid compartments before parturition in a primate species," *The Journal of Clinical Endocrinology & Metabolism*, vol. 58, no. 4, pp. 629–634, 1984.

O. M. Avrech, A. Golan, Z. Weinraub, I. Bukovsky, and E. Caspi, "Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review," *Fertility and Sterility*, vol. 56, no. 3, pp. 385–393, 1991.

X. Fang, S. Wong, and B. F. Mitchell, "Effects of RU486 on estrogen, progesterone, oxtocin, and their receptors in the rat uterus during late gestation," *Endocrinology*, vol. 138, no. 7, pp. 2763–2768, 1997.

G. J. Haluska, C. A. Kaler, M. J. Cook, and M. J. Novy, "Prostaglandin production during spontaneous labor and after treatment with RU486 in pregnant thucis macaques," *Biology of Reproduction*, vol. 51, no. 4, pp. 760–765, 1994.

S. Mesiano and T. N. Welsh, "Steroid hormone control of myometrial contractility and parturition," *Seminars in Cell and Developmental Biology*, vol. 18, no. 3, pp. 321–331, 2007.

L. Nadeem, O. Slynlova, E. Matsyiak-Zablocki, S. Mesiano, X. Dong, and S. Lye, "Molecular evidence of functional progesterone withdrawal in human myometrium," *Nature Communications*, vol. 7, article 11565, 2016.

P. H. Giangrande and D. P. McDonnell, "The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene," *Recent Prog Horm Res*, vol. 54, pp. 291–314, 1999.

G. J. Haluska, T. R. Wells, J. J. Hirst, R. M. Brenner, D. W. Sadowsky, and M. J. Novy, "Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from thucis macaques: evidence for functional progesterone withdrawal at parturition," *Journal of the Society for Gynecologic Investigation*, vol. 9, no. 3, pp. 125–136, 2002.

A. A. Merlino, T. N. Welsh, H. Tan et al., "Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A," *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 5, pp. 1927–1933, 2007.

S. Mesiano, E.-C. Chan, J. T. Fitter, K. Kwek, G. Yeo, and R. Smith, "Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium," *Journal of Clinical Endocrinology and Metabolism*, vol. 87, no. 6, pp. 2924–2930, 2002.

L. Hayflick and P. S. Moorhead, "The serial cultivation of human diploid cell strains," *Experimental Cell Research*, vol. 25, no. 3, pp. 585–621, 1961.

A. G. Bodnar, M. Ouellette, M. Frolikis et al., "Extension of lifespan by introduction of telomerase into normal human cells," *Science*, vol. 279, no. 5349, pp. 349–352, 1998.

P. Chapdelaine, J. Kang, S. Boucher-Kovalik, N. Caron, J. P. Tremblay, and M. A. Fortier, "Decidualization and maintenance of a functional prostaglandin system in human endometrial cell lines following transformation with SV40 large T antigen," *Molecular Human Reproduction*, vol. 12, no. 5, pp. 309–319, 2006.

N. Perez-Reyes, C. L. Halbert, P. P. Smith, E. P. Benditt, and J. K. McDouggall, "Immortalization of primary human smooth muscle cells," *Proceedings of the National Academy of Sciences*, vol. 89, no. 4, pp. 1224–1228, 1992.

J. Qian, E. M. Hendrix, W. J. Larsen, G. W. Dorn II, and J. L. Lessard, "Establishment and characterization of a conditionally immortalized smooth muscle/myometrial-like cell line," *Molecular Reproduction and Development*, vol. 47, no. 3, pp. 284–294, 1997.

L. Anderson, W. Martin, C. Higgins, S. M. Nelson, and J. E. Norman, "The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy," *Reproductive Sciences*, vol. 16, no. 11, pp. 1052–1061, 2009.

J. Baumbach, S.-Q. Shi, L. Shi, J. Balducci, D. V. Coonrod, and R. E. Garfield, "Inhibition of uterine contractility with various tocolytics with and without progesterone: in vitro studies," *American Journal of Obstetrics and Gynecology*, vol. 206, no. 3, pp. 254.e1–254.e5, 2012.

N. K. Ruddock, S.-Q. Shi, S. Jain et al., "Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions," *American Journal of Obstetrics and Gynecology*, vol. 199, no. 4, pp. 391.e1–391.e7, 2008.

E. K. Tyson, R. Smith, and M. Read, "Evidence that corticotropin-releasing hormone modulates myometrial contractility during human pregnancy," *Endocrinology*, vol. 150, no. 12, pp. 5617–5625, 2009.

C. A. Hudson, K. J. Heesom, and A. L. Bernal, "Phasic contractions of isolated human myometrium are associated with rhokinase (ROCK)-dependent phosphorylation of myosin phosphatase-targeting subunit (MYPT1)," *Molecular Human Reproduction*, vol. 18, no. 5, pp. 265–279, 2012.

J. Paul, K. Maiti, M. Read et al., "Phasic Phosphorylation of Caldesmon and ERK 1/2 during contractions in Human Myometrium," *PLoS ONE*, vol. 6, no. 6, Article ID e21542, 2011.

K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.

A. A. Mosher, K. J. Rainey, S. S. Bolstad et al., "Development and validation of primary human myometrial cell culture models to study pregnancy and labour," *BJM. Pregnancy Childbirth*, vol. 13, supplement 1, article S7, 2013.

Y. Cordeaux, M. Tattersall, D. S. Charnock-Jones, and G. C. Smith, "Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women," *Endocrine Reviews*, vol. 31, no. 5, pp. E437–E447, 2010.

N. Chegini, C. Ma, X. M. Tang, and R. S. Williams, "Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-β expression," *Molecular Human Reproduction*, vol. 8, no. 12, pp. 1071–1078, 2002.
T. Welsh, M. Johnson, L. Yi et al., “Estrogen receptor (ER) expression and function in the pregnant human myometrium: Estradiol via ERα activates ERK1/2 signaling in term myometrium,” *Journal of Endocrinology*, vol. 212, no. 2, pp. 227–238, 2012.

J. W. Paul, S. Hua, M. Ilici et al., “Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor,” *American Journal of Obstetrics and Gynecology*, vol. 216, no. 3, pp. 283.e1–283.e14, 2017.

M. Rezapour, T. Bäckström, B. Lindblom, and U. Ulmsten, “Sex steroid receptors and human parturition,” *Ostetrics and Gynecology*, vol. 89, no. 6, pp. 918–924, 1997.

D. Pieber, V. C. Allport, F. Hills, M. Johnson, and P. R. Bennett, “Interactions between progesterone receptor isoforms in myometrial cells in human labour,” *Molecular Human Reproduction*, vol. 7, no. 9, pp. 875–879, 2001.

J. R. G. Challis, S. G. Matthews, W. Gibb, and S. J. Lye, “Endocrine and paracrine regulation of birth at term and preterm,” *Endocrine Reviews*, vol. 21, no. 5, pp. 514–550, 2000.

E. R. Norwitz, J. N. Robinson, and J. R. G. Challis, “The control of labor,” *New England Journal of Medicine*, vol. 341, no. 9, pp. 660–666, 1999.

R. De Hertogh, K. Thomas, Y. Bietlot, I. Vanderheyden, and J. Ferin, “Plasma levels of unconjugated estrone, estradiol and estriol and of HCS throughout pregnancy in normal women,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 40, no. 1, pp. 93–101, 1975.

R. Smith, J. I. Smith, X. Shen et al., “Patterns of plasma corticotropin-releasing hormone, progesterone, estradiol, and estriol and the onset of human labor,” *J Clin Endocrinol Metab*, vol. 94, no. 6, pp. 2066–2074, 2009.

B. S. Katzenellenbogen, “Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways,” *Journal of the Society for Gynecologic Investigation*, vol. 7, no. 1, pp. S33–S37, 2000.

B. S. Katzenellenbogen, A. M. Nardulli, and L. D. Read, “Estrogen regulation of proliferation and hormonal modulation of estrogen and progesterone receptor biosynthesis and degradation in target cells,” *Progress in Clinical and Biological Research*, vol. 322, pp. 201–211, 1990.

J. A. Z. Loudon, S. R. Sooranna, P. R. Bennett, and M. R. Johnson, “Mechanical stretch of human uterine smooth muscle cells increases IL-8 mRNA expression and peptide synthesis,” *Molecular Human Reproduction*, vol. 10, no. 12, pp. 895–899, 2004.

S. R. Sooranna, Y. Lee, L. U. Kim, A. R. Mohan, P. R. Bennett, and M. R. Johnson, “Mechanical stretch activates type 2 cyclooxygenase via activator protein-1 transcription factor in human myometrial cells,” *Molecular Human Reproduction*, vol. 10, no. 2, pp. 109–113, 2004.

K. Lei, L. Chen, B. J. Cryan et al., “Uterine stretch and progesterone action,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 96, no. 6, pp. E1013–E1024, 2011.

C.-W. Ou, Z.-Q. Chen, S. Qi, and S. J. Lye, “Increased expression of the rat myometrial oxytocin receptor messenger ribonucleic acid during labor requires both mechanical and hormonal signals,” *Biology of Reproduction*, vol. 59, no. 5, pp. 1055–1061, 1998.

C.-W. Ou, A. Orsino, and S. J. Lye, “Expression of connexin-43 and connexin-26 in the rat myometrium during pregnancy and labor is differentially regulated by mechanical and hormonal signals,” *Endocrinology*, vol. 138, no. 12, pp. 5398–5407, 1997.

L. J. Parry and R. A. Bathgate, “The role of oxytocin and regulation of uterine oxytocin receptors in pregnant marsupials,” *Experimental Physiology*, vol. 85, pp. 91s–99s, 2000.

W. X. Wu, X. H. Ma, T. Yoshizato, N. Shinozuka, and P. W. Nathanielz, “Differential expression of myometrial oxytocin receptor and prostaglandin H synthase 2, but not estrogen receptor α and heat shock protein 90 messenger ribonucleic acid in the gravid horn and nongravid horn in sheep during betamethasone-induced labor,” *Endocrinology*, vol. 140, no. 12, pp. 5712–5718, 1999.

Y.-L. Dong, L. Fang, S. Kondapaka, P. R. Gangula, S. J. Wima-lawansa, and C. Vallampalli, “Involvement of calcitonin gene-related peptide in the modulation of human myometrial contractility during pregnancy,” *Journal of Clinical Investigation*, vol. 104, no. 5, pp. 559–565, 1999.

G. N. Europe-Finner, S. Phaneuf, A. M. Tolkovsky, S. P. Watson, and A. Lopez Bernal, “Down-regulation of G alpha s in human myometrium in term and preterm labor: a mechanism for parturition,” *Journal of Clinical Endocrinology & Metabolism*, vol. 79, no. 6, pp. 1833–1839, 1994.

G. N. Europe-Finner, S. Phaneuf, S. P. Watson, and A. L. Bernal, “Identification and expression of G-proteins in human myometrium: up-regulation of Gas in pregnancy,” *Endocrinology*, vol. 132, no. 6, pp. 2484–2490, 1993.

A. Lopez Bernal, J. Rivera, G. N. Europe-Finner, S. Phaneuf, and G. Asboth, “Parturition: activation of stimulatory pathways or loss of uterine quiescence?” *Advances in Experimental Medicine and Biology*, no. 395, pp. 435–451, 1995.

J. Zuo, Z. M. Lei, and C. V. Rao, “Human myometrial chorionic gonadotropin/luteinizing hormone receptors in preterm and term deliveries,” *Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 3, pp. 907–911, 1994.

G. Madsen, T. Zakar, C. Y. Ku, B. M. Sanborn, R. Smith, and S. Mesiano, “Prostaglandins differentially modulate progesterone receptor-A and -B expression in human myometrial cells: evidence for prostaglandin-induced functional progesterone withdrawal,” *Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 2, pp. 1001–1013, 2004.

W. Elger and S. G. Hasan, “Studies on the mechanism of action of antifertile PG in animal models,” *Acta Physiol Hung*, vol. 65, no. 4, pp. 415–32, 1985.

W. Elger, S. H. Hasan, and E. Friedreich, “‘Uterine’ and ‘luteal’ effects of prostaglandins (PG) in rats and guinea pigs as potential abortifacient mechanisms,” *Acta Endocrinologica Supplement*, vol. 173, p. 46, 1973.

Y. Sugimoto, A. Yamasaki, E. Segi et al., “Failure of parturition in mice lacking the prostaglandin F receptor,” *Science*, vol. 277, no. 5326, pp. 681–683, 1997.

M. Embrey, “PGE compounds for induction of labour and abortion,” *Annals of the New York Academy of Sciences*, vol. 180, no. 1, pp. 518–523, 1971.

M. P. Embrey, “Prostaglandins in human reproduction,” *British Medical Journal (Clinical Research ed.)*, vol. 283, no. 6306, pp. 1563–1566, 1981.
[72] J. K. Jain and D. R. Mishell Jr., “A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy,” *New England Journal of Medicine*, vol. 331, no. 5, pp. 290–293, 1994.

[73] J. Robins and L. I. Mann, “Midtrimester pregnancy termination by intramuscular injection of a 15 methyl analogue of prostaglandin F2 alpha,” *American Journal of Obstetrics and Gynecology*, vol. 123, no. 6, pp. 625–631, 1975.

[74] R. Romero, J. Espinoza, L. F. Gonçalves, J. P. Kusanovic, L. Friel, and S. Hassan, “The role of inflammation and infection in preterm birth,” *Seminars in Reproductive Medicine*, vol. 25, no. 1, pp. 21–39, 2007.

[75] P. Mittal, R. Romero, A. L. Tarca et al., “Characterization of the myometrial transcriptome and biological pathways of spontaneous human labor at term,” *Journal of Perinatal Medicine*, vol. 38, no. 6, pp. 617–643, 2010.

[76] J. E. Norman, S. Bollapragada, M. Yuan, and S. M. Nelson, “Inflammatory pathways in the mechanism of parturition,” *BMC Pregnancy and Childbirth*, vol. 7, supplement 1, article S7, 2007.

[77] I. Osman, A. Young, M. A. Ledingham et al., “Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term,” *Molecular Human Reproduction*, vol. 9, no. 1, pp. 41–45, 2003.

[78] A. J. Thomson, J. F. Telfer, A. Young et al., “Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process,” *Human Reproduction*, vol. 14, no. 1, pp. 229–236, 1999.

[79] A. Young, A. J. Thomson, M. Ledingham, F. Jordan, I. A. Greer, and J. E. Norman, “Immunolocalization of proinflammatory cytokines in myometrium, cervix, and fetal membranes during human parturition at term,” *Biology of Reproduction*, vol. 66, no. 2, pp. 445–449, 2002.

[80] T. M. Lindström and P. R. Bennett, “The role of nuclear factor kappa B in human labour,” *Reproduction*, vol. 130, no. 5, pp. 569–581, 2005.

[81] D. B. Hardy, B. A. Janowski, D. R. Corey, and C. R. Mendelson, “Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-κB activation of cyclooxygenase 2 expression,” *Molecular Endocrinology*, vol. 20, no. 11, pp. 2724–2733, 2006.

[82] J. C. Condon, P. Jeyasuria, J. M. Faust, J. W. Wilson, and C. R. Mendelson, “A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 16, pp. 9518–9523, 2003.

[83] M. A. Wilson, A. R. Ricci, B. J. Deroo, and T. K. Archer, “The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo,” *Journal of Biological Chemistry*, vol. 277, no. 17, pp. 15171–15181, 2002.

[84] M. van Zijl, B. Koullali, B. W. Mol, E. Pajkrt, and M. Oudijk, “Prevention of preterm delivery: current challenges and future prospects,” *International Journal of Women’s Health*, vol. 8, pp. 633–645, 2016.